Added daily report

2021-08-13 12:51:08 +00:00 · 2021-08-13 12:51:08 +00:00 · eaddd2961d
parent 9f30d3f3bb
commit eaddd2961d
3 changed files with 1464 additions and 2 deletions
--- a/archive-covid-19/13
+++ b/archive-covid-19/13
@ -0,0 +1,204 @@
 <!DOCTYPE html>
 <html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
  <meta charset="utf-8"/>
  <meta content="pandoc" name="generator"/>
  <meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
  <title>13 August, 2021</title>
  <style type="text/css">
      code{white-space: pre-wrap;}
      span.smallcaps{font-variant: small-caps;}
      span.underline{text-decoration: underline;}
      div.column{display: inline-block; vertical-align: top; width: 50%;}
  </style>
 <title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
 <body>
 <h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
 <h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
 <ul>
 <li><a href="#from-preprints">From Preprints</a></li>
 <li><a href="#from-clinical-trials">From Clinical Trials</a></li>
 <li><a href="#from-pubmed">From PubMed</a></li>
 <li><a href="#from-patent-search">From Patent Search</a></li>
 </ul>
 <h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
 <ul>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Behavioral activation method for depression therapy</strong> -
 <div>
 Under the lockdown of COVID-19 infection, a dramatic decline in social contacts, a radical change in daily life routine, economic problems, a real threat to one’s own life, and the death of loved ones have led to depression in many people of all ages. In the arsenal of methods used by psychologist consultants when conducting telephone and online consultations, it is recommended to use the method of behavioral activation. Behavioral activation is a structured, short-term psychosocial approach that aims to alleviate depression and prevent future relapse by focusing directly on behavioral change. The article includes a discussion of the characteristics of the behavioral activation method.
 </div></li>
 </ul>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://psyarxiv.com/ge8s3/" target="_blank">Behavioral activation method for depression therapy</a>
 </div>
 <ul>
 <li><strong>A Week During COVID-19: Online Social Interactions Predict Greater Connection and More Stress</strong> -
 <div>
 Who thrives while socially distancing? For this descriptive, exploratory study, we polled a sample of over 500 participants from the United States on April 8, 2020—in the early stages of the COVID-19 pandemic when practicing social distancing was at its peak. Above and beyond other social and nonsocial activities, living and employment arrangements, personality traits, demographics, and other variables, people who spent more time interacting with close others—either in person or online—felt more socially connected. However, only interacting with close others in person, but not online, predicted greater positive affect. In contrast, people who spent more time interacting with weak ties online experienced greater negative affect and more stress. Looking at specific interaction partners, we found that people who interacted with their relatives, romantic partners, and even coworkers/classmates felt more socially connected. Living arrangements mattered little beyond people’s social interactions, except for living with one’s children, which predicted greater stress. Certain social online activities, including playing games with close ties and group/club meetings predicted greater positive affect. Amongst nonsocial activities, active leisure like exercise emerged as a robust predictor of positive affect, whereas passive leisure like watching TV predicted greater negative affect. Even during a historic pandemic and unprecedented conditions of social distancing, then, the factors that predict well-being are much the same as those already established in the literature. Indeed, much like in-person interactions, online social interactions predict greater social connectedness. However, unlike in-person interactions, online interactions simultaneously predict more negative affect and more stress.
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://psyarxiv.com/7gjkc/" target="_blank">A Week During COVID-19: Online Social Interactions Predict Greater Connection and More Stress</a>
 </div></li>
 <li><strong>Overlapping Time Scales Obscure Early Warning Signals of the Second COVID-19 Wave</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 Early warning indicators based on critical slowing down have been suggested as a model-independent and low-cost tool to anticipate the (re)emergence of infectious diseases. We studied whether such indicators could reliably have anticipated the second COVID-19 wave in European countries. Contrary to theoretical predictions, we found that characteristic early warning indicators generally decreased rather than increased prior to the second wave. A model explains this unexpected finding as a result of transient dynamics and the multiple time scales of relaxation during a non-stationary epidemic. Particularly, if an epidemic that seems initially contained after a first wave does not fully settle to its new quasi-equilibrium prior to changing circumstances or conditions that force a second wave, then indicators will show a decreasing rather than an increasing trend as a result of the persistent transient trajectory of the first wave. Our simulations show that this lack of time scale separation was to be expected during the second European epidemic wave of COVID-19. Overall, our results emphasize that the theory of critical slowing down applies only when the external forcing of the system across a critical point is slow relative to the internal system dynamics.
 </p>
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.07.27.21261226v3" target="_blank">Overlapping Time Scales Obscure Early Warning Signals of the Second COVID-19 Wave</a>
 </div></li>
 <li><strong>Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 Background: Monoclonal antibodies (mAbs) against SARS-CoV-2 are a promising treatment for limiting the progression of COVID-19 and decreasing strain on hospitals. Their use, however, remains limited, particularly in disadvantaged populations. Methods: Electronic health records were reviewed from SARS-CoV-2 patients at a single medical center in the United States that initiated mAb infusions in January 2021 with the support of the U.S. Department of Health and Human Services9 National Disaster Medical System. Patients who received mAbs were compared to untreated patients from the time period before mAb availability who met eligibility criteria for mAb treatment. We used logistic regression to measure the effect of mAb treatment on the risk of hospitalization or emergency department (E.D.) visit within 30 days of laboratory-confirmed COVID-19. Results: Of 598 COVID-19 patients, 270 (45%) received bamlanivimab and 328 (55%) were untreated. Two hundred and thirty-one patients (39%) were Hispanic. Among treated patients, 5/270 (1.9%) presented to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared to 39/328 (12%) untreated patients (p&lt;0.001). After adjusting for age, gender, and comorbidities, the risk of E.D. visit or hospitalization was 82% lower in mAb-treated patients compared to untreated patients (95% confidence interval [CI]: 66%-94%). Conclusions: In this diverse, real-world COVID-19 patient population, mAb treatment significantly decreased the risk of subsequent E.D. visit or hospitalization. Broader treatment with mAbs, including in disadvantaged patient populations, can decrease the burden on hospitals and should be facilitated in all populations in the United States to ensure health equity.
 </p>
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.04.08.21254705v2" target="_blank">Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States</a>
 </div></li>
 <li><strong>Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and variants of concern</strong> -
 <div>
 To understand the nature of the antibody response to SARS-CoV-2 vaccination, we analyzed at single cell level the B cell responses of five naive and five convalescent people immunized with the BNT162b2 mRNA vaccine. Convalescents had higher frequency of spike protein specific memory B cells and by cell sorting delivered 3,532 B cells, compared with 2,352 from naive people. Of these, 944 from naive and 2,299 from convalescents produced monoclonal antibodies against the spike protein and 411 of them neutralized the original Wuhan SARS-CoV-2 virus. More than 75% of the monoclonal antibodies from naive people lost their neutralization activity against the B.1.351 (beta) and B.1.1.248 (gamma) variants while this happened only for 61% of those from convalescents. The overall loss of neutralization was lower for the B.1.1.7 (alpha) and B.1.617.2 (delta) variants, however it was always significantly higher in those of naive people. In part this was due to the IGHV2-5;IGHJ4-1 germline, which was found only in convalescents and generated potent and broadly neutralizing antibodies. Overall, vaccination of seropositive people increases the frequency of B cells encoding antibodies with high potency and that are not susceptible to escape by any of the four variants of concern. Our data suggest that people that are seropositive following infection or primary vaccination will produce antibodies with increased potency and breadth and will be able to better control SARS-CoV-2 emerging variants.
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.12.456077v1" target="_blank">Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and variants of concern</a>
 </div></li>
 <li><strong>In vitro determination of inhibitory effects by humic substances complexing Zn and Se on SARS-CoV-2 virus replication</strong> -
 <div>
 Humic substances are well known human nutritional supplement materials and play important performance-enhancing roles as animal feed additives, too. For decades, ingredients of humic substances have also been proven to carry potent antiviral effects against different viruses. Here, the antiviral activity of a humic substance containing ascorbic acid, Se- and Zn2+ ions intended as a nutritional supplement material was investigated against SARS-CoV-2 virus B1.1.7 Variant of Concern (Alpha Variant) in a VeroE6 cell line. Results show that this combination has a significant in vitro antiviral effect at a very low concentration range of its intended active ingredients. Even picomolar concentration ranges of humic substances, vitamin C and Zn/Se ions in the given composition were enough to achieve fifty percent viral replication inhibition in the applied SARS-CoV-2 virus inhibition test. Keywords: SARS-CoV-2, humic acid, fulvic acid, Zn-Se-ascorbic acid complex, antiviral activity, RT-PCR
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.11.456012v1" target="_blank">In vitro determination of inhibitory effects by humic substances complexing Zn and Se on SARS-CoV-2 virus replication</a>
 </div></li>
 <li><strong>Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates</strong> -
 <div>
 Neutralizing antibody responses gradually wane after vaccination with mRNA-1273 against several variants of concern (VOC), and additional boost vaccinations may be required to sustain immunity and protection. Here, we evaluated the immune responses in nonhuman primates that received 100 g of mRNA-1273 vaccine at 0 and 4 weeks and were boosted at week 29 with mRNA-1273 (homologous) or mRNA-1273.{beta} (heterologous), which encompasses the spike sequence of the B.1.351 (beta or {beta}) variant. Reciprocal ID50 pseudovirus neutralizing antibody geometric mean titers (GMT) against live SARS-CoV-2 D614G and the {beta} variant, were 4700 and 765, respectively, at week 6, the peak of primary response, and 644 and 553, respectively, at a 5-month post-vaccination memory time point. Two weeks following homologous or heterologous boost {beta}-specific reciprocal ID50 GMT were 5000 and 3000, respectively. At week 38, animals were challenged in the upper and lower airway with the {beta} variant. Two days post-challenge, viral replication was low to undetectable in both BAL and nasal swabs in most of the boosted animals. These data show that boosting with the homologous mRNA-1273 vaccine six months after primary immunization provides up to a 20-fold increase in neutralizing antibody responses across all VOC, which may be required to sustain high-level protection against severe disease, especially for at-risk populations.
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.11.456015v1" target="_blank">Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates</a>
 </div></li>
 <li><strong>Robust and Functional Immunity up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort</strong> -
 <div>
 Assessing the duration of humoral and cellular immunity remains key to overcome the current SARS-CoV-2 pandemic, especially in understudied populations in least developed countries. Sixty-four Cambodian individuals with laboratory- confirmed infection with asymptomatic or mild/moderate clinical presentation were evaluated for humoral immune response to the viral spike protein and antibody effector functions during acute phase of infection and at 6-9 months follow-up. Antigen-specific B cells, CD4+ and CD8+ T cells were characterized, and T cells were interrogated for functionality at late convalescence. Anti-spike (S) antibody titers decreased over time, but effector functions mediated by S-specific antibodies remained stable. S- and nucleocapsid (N)-specific B cells could be detected in late convalescence in the activated memory B cell compartment and are mostly IgG+. CD4+ and CD8+ T cell immunity was maintained to S and membrane (M) protein. Asymptomatic infection resulted in decreased ADCC and frequency of SARS- CoV-2-specific CD4+ T cells at late convalescence. Whereas anti-S antibodies correlated with S-specific B cells, there was no correlation between T cell response and humoral immunity. Hence, all aspects of a protective immune response are maintained up to nine months after SARS-CoV-2 infection in the absence of re-infection.
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.12.455901v1" target="_blank">Robust and Functional Immunity up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort</a>
 </div></li>
 <li><strong>The D614G virus mutation enhances anosmia in COVID-19 patients: Evidence from a systematic review and meta-analysis of studies from South Asia</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 The prevalence of chemosensory dysfunction in patients with COVID-19 varies greatly between populations. It is unclear whether such differences are due to factors at the level of the human host, or at the level of the coronavirus, or both. At the host level, the entry proteins which allow virus binding and entry have variants with distinct properties, and the frequency of such variants differs between ethnicities. At the level of the virus, the D614G mutation enhances virus entry to the host cell. Since the two virus strains (D614 and G614) co-existed in the first six months of the pandemic in most populations, it has been difficult to distinguish between contributions of the virus and contributions of the host for anosmia. To answer this question, we conducted a systematic review and meta-analysis of studies in South Asian populations when either the D614 or the G614 virus was dominant. We show that populations infected predominantly with the G614 virus had a much higher prevalence of anosmia (pooled prevalence of 31.8%) compared with the same ethnic populations infected mostly with the D614 virus strain (pooled anosmia prevalence of 5.3%). We conclude that the D614G mutation is a major contributing factor that increases the prevalence of anosmia in COVID-19, and that this enhanced effect on olfaction constitutes a previously unrecognized phenotype of the D614G mutation. The new virus strains that have additional mutations on the background of the D614G mutation can be expected to cause a similarly increased prevalence of chemosensory dysfunctions.
 </p>
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.11.21261934v1" target="_blank">The D614G virus mutation enhances anosmia in COVID-19 patients: Evidence from a systematic review and meta-analysis of studies from South Asia</a>
 </div></li>
 <li><strong>Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India-A cohort study</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 Abstract Background The second wave of the COVID-19 pandemic hit India from early April 2021 to June 2021 and more than 400,000 cases per day were reported in the country. We describe the clinical features, demography, treatment trends, baseline laboratory parameters of a cohort of patients admitted at the All India Institute of Medical Sciences, New Delhi with SARS-CoV-2 infection and their association with the outcome. Methods This was a retrospective cohort study describing the clinical, laboratory and treatment patterns of consecutive patients admitted with SARS-CoV-2 infection. Multivariate logistic regression models were fitted to identify the clinical and biochemical predictors of developing hypoxia, deterioration during the hospital stay and death. Findings A total of 2080 patients were included in the study. The case fatality rate was 19.5%. Amongst the survivors, the median duration of hospital stay was 8 (5-11) days. Out of 853 (42.3%%) of patients who had COVID-19 Acute respiratory distress syndrome at presentation, 340 (39.9%) died. Patients aged 45-60 years [OR (95% CI): 1.8 (1.2-2.6)p =0.003] and those aged &gt;60 years [OR (95%CI): 3.4 (2.3-5.2), p&lt;0.001] had a higher odds of death as compared to the 18-44 age group. Vaccination reduced the odds of death by 30% [OR (95% CI): 0.7 (0.5-0.9), p=0.036]. Patients with hyper inflammation at baseline as suggested by leucocytosis [OR (95% CI): 2.1 (1.4-3.10), p &lt;0.001], raised d-dimer &gt;500 mg/dL [OR (95% CI): 3.2 (2.2-4.6), p &lt;0.001] and raised C-reactive peptide &gt;0.5 mg/L [OR (95% CI): 3.8 (1.1-13), p=0.037] had higher odds of death. Patients who were admitted in the second week had lower odds of death and those admitted in the third week had higher odds of death. Interpretation This is the largest cohort of patients admitted with COVID-19 from India reported to date and has shown that vaccination status and early admission during the inflammatory phase can change the course of illness of these patients. Strategies should be made to improve vaccination rates and early admission of patients with moderate and severe COVID-19 to improve outcomes.
 </p>
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.10.21261855v1" target="_blank">Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India-A cohort study</a>
 </div></li>
 <li><strong>Data analysis of COVID-19 wave peaks in relation to latitude and temperature for multiple nations</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 It was observed that the multiple peaks of coronavirus disease 19 (COVID 19) appeared in different seasons in different countries. There were countries where the COVID-19 peak occurred during extremely low temperatures, such as Norway, Canada and on the other hand there were countries with high-temperature ranges such as Brazil, India, UAE. Most of the high-latitude countries received their outbreak in winter and most of the countries near the equator mark the outbreak during the summer. Most of the biological organisms have their growth dependent on the temperature, and hence we explored that if there is any relation of temperature versus COVID-19 outbreak in the particular country. It was also seen that people are not behaving differently during the peak of the COVID-19 wave, hence it was important to know whether the COVID-19 virus has evolved or the global temperature variation caused these multiple peaks. This work focuses on finding the effect of temperature variation on the COVID-19 outbreak. We used Levenberg Marquardt technique to find the correlation between the temperature at which COVID-19 outbreak peaks and the latitude of the particular country. We found that between the temperature range of 14 Degree C to 20 Degree C spread of the COVID-19 is minimal. Based on our results we can also say that the COVID-19 outbreak is seen in lower temperature (0 Degree C to 13 Degree C) ranges as well as in the higher temperature ranges (21 Degree C to 35 Degree C). The current data analysis will help the authorities to manage their resources in advance to prepare for any further outbreaks that might occur in the COVID-19 or even in the next pandemic.
 </p>
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.12.21261974v1" target="_blank">Data analysis of COVID-19 wave peaks in relation to latitude and temperature for multiple nations</a>
 </div></li>
 <li><strong>Geospatial Variability in Excess Death Rates during the COVID-19 Pandemic in Mexico: Examining Socio Demographic and Population Health Characteristics</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 Background: Mexico has suffered one of the highest COVID-19 mortality rates in the world. In this study we examined how socio-demographic and population health characteristics shape the geospatial variability in excess mortality patterns during the COVID-19 pandemic in Mexico. Methods: Weekly all-cause mortality time series for all 32 Mexican states, from January 4, 2015 to April 10, 2021, were analyzed to estimate the excess mortality rates using Serfling regression models. The association between socio-demographic, health indicators and excess mortality rates were determined using multiple linear regression analyses. Finally, we used functional data analysis to characterize clusters of states with distinct mortality growth rate curves. Results: The overall all-cause excess deaths rate during the COVID-19 pandemic in Mexico until April 10, 2021 was estimated at 39.66 per 10 000 population. The lowest excess death rates were observed in southeastern states including Chiapas (12.72), Oaxaca (13.42) and Quintana Roo (19.41) whereas Mexico City had the highest excess death rate (106.17), followed by Tlaxcala (51.99) and Morelos (45.90). We found a positive association of excess mortality rates with aging index (P value&lt;.0001), marginalization index (P value&lt;.0001), and average household size (P value=0.0003) in the final adjusted model (Model R2=76%). We identified four distinct clusters with qualitatively similar excess mortality curves. Conclusion: Central states exhibited the highest excess mortality rates whereas the distribution of aging index, marginalization index, and average household size explained the variability in excess mortality rates across Mexico. Our findings can help tailor interventions to mitigate the mortality impact of the pandemic.
 </p>
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.11.21261930v1" target="_blank">Geospatial Variability in Excess Death Rates during the COVID-19 Pandemic in Mexico: Examining Socio Demographic and Population Health Characteristics</a>
 </div></li>
 <li><strong>B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant Recipients</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 Background: Accumulating evidence suggests that solid organ transplant recipients, as opposed to the general population, show strongly impaired responsiveness towards standard SARS-CoV-2 mRNA-based vaccination, demanding alternative strategies for protection of this vulnerable group. Methods: In line with recent recommendations, a third dose of either heterologous ChAdOx1 (AstraZeneca) or homologous BNT162b2 (BioNTech) was administered to 25 kidney transplant recipients (KTR) without humoral response after 2 doses of BNT162b2, followed by analysis of serological responses and vaccine-specific B- and T-cell immunity. Results: 9/25 (36%) KTR under standard immunosuppressive treatment seroconverted until day 27 after the third vaccination, while one patient developed severe COVID-19 infection immediately after vaccination. Cellular analysis seven days after the third dose showed significantly elevated frequencies of viral spike protein receptor binding domain specific B cells in humoral responders as compared to non- responders. Likewise, portions of spike-reactive CD4+ T helper cells were significantly elevated in seroconverting patients. Furthermore, overall frequencies of IL-2+, IL-4+ and polyfunctional CD4+ T cells significantly increased after the third dose, whereas memory/effector differentiation remained unaffected. Conclusions: Our data suggest that a fraction of transplant recipients benefits from triple vaccination, where seroconversion is associated with quantitative and qualitative changes of cellular immunity. At the same time, the study highlights that modified vaccination approaches for immunosuppressed patients still remain an urgent medical need.
 </p>
 </div>
 <div class="article- link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.12.21261966v1" target="_blank">B and T cell responses after a third dose of SARS-CoV-2 vaccine in Kidney Transplant Recipients</a>
 </div></li>
 <li><strong>A SARS-CoV-2 mini-genome assay based on negative-sense RNA to study replication inhibitors and emerging mutations</strong> -
 <div>
 Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus and the causative agent of the Coronavirus disease 2019 (COVID-19) pandemic. Efforts to identify inhibitors of SARS-CoV-2 replication enzymes and better understand the mechanisms underlying viral RNA synthesis have largely relied on biosafety level 3 (BSL3) laboratories, limiting throughput and accessibility. Recently, replicon systems have been proposed that involve ~30 kb RNA-based replicons or large plasmids that express the viral structural and non-structural proteins (nsp) in addition to a positive-sense reporter RNA. Unfortunately, these assays are not user-friendly due to plasmid instability or a poor signal to background ratio. We here present a simple mini-genome assay consisting of a ~2.5 kb-long negative- sense, nanoluciferase-encoding sub-genomic reporter RNA that is expressed from a plasmid, and amplified and transcribed by the SARS-CoV-2 RNA polymerase core proteins nsp7, nsp8 and nsp12. We show that expression of nsp7, 8 and 12 is sufficient to obtain robust positive- and negative-sense RNA synthesis in cell culture, that addition of other nsps modulates expression levels, and that replication of the reporter RNA can be inhibited by active site mutations in nsp12 or the SARS-CoV-2 replication inhibitor remdesivir. The mini-genome assay provides a signal that is 170-fold above background on average, providing excellent sensitivity for high-throughput screens, while the use of small plasmids facilitates site-directed mutagenesis for fundamental analyses of SARS-CoV-2 RNA synthesis.
 </div>
 <div class="article- link article-html-link">
 🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.06.28.450211v2" target="_blank">A SARS-CoV-2 mini-genome assay based on negative-sense RNA to study replication inhibitors and emerging mutations</a>
 </div></li>
 <li><strong>Specificity of SARS-CoV-2 antibody-detection assays against S and N protein among pre-COVID-19 sera from patients with protozoan and helminth parasitic infections</strong> -
 <div>
 <p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
 Background: We aimed to assess the specificity of SARS-CoV-2 antibody detection assays among people with known tissue-borne parasitic infections. Methods: We tested three SARS-CoV-2 antibody-detection assays (cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Abbott SARS-CoV-2 IgG assay, and STANDARD Q COVID-19 IgM/IgG Combo Rapid Test) among 559 pre-COVID-19 sera. Results: The specificity of assays was 95-98% overall. However, lower specificity was observed among sera from patients with protozoan infections of the reticuloendothelial system, such as human African trypanosomiasis (Abbott Architect; 88% [95%CI 75-95]), visceral leishmaniasis (SD RDT IgG; 80% [95%CI 30-99]), and from patients with recent malaria from a holoendemic area of Senegal (ranging from 91% for Abbott Architect and SD RDT IgM to 98-99% for cPass and SD RDT IgG). For specimens from patients with evidence of past or present helminth infection overall, test specificity estimates were all ≥ 96%. Sera collected from patients clinically suspected of parasitic infections that tested negative for these infections yielded a specificity of 98-100%. The majority (&gt;85%) of false- positive results were positive by only one assay. Conclusions: The specificity of SARS-CoV-2 serological assays among sera from patients with tissue-borne parasitic infections was below the threshold required for decisions about individual patient care. Specificity is markedly increased by the use of confirmatory testing with a second assay. Finally, the SD RDT IgG proved similarly specific to laboratory-based assays and provides an option in low-resource settings when detection of anti-SARS-CoV-2 IgG is indicated.
 </p>
 </div>
 <div class="article-link article-html-link">
 🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.10.21261841v1" target="_blank">Specificity of SARS-CoV-2 antibody-detection assays against S and N protein among pre-COVID-19 sera from patients with protozoan and helminth parasitic infections</a>
 </div></li>
 </ul>
 <h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
 <ul>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pulmonary Rehabilitation Post-COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Other: Exercise program (virtual/remote)<br/><b>Sponsors</b>:   University of Manitoba;   Health Sciences Centre Foundation, Manitoba;   Health Sciences Centre, Winnipeg, Manitoba<br/><b>Not yet recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 “Long Haul” Pulmonary Compromise</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: COVI-MSC;   Biological: Placebo<br/><b>Sponsor</b>:   Sorrento Therapeutics, Inc.<br/><b>Not yet recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines in Mozambique</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell);   Biological: AZD1222 (replication-deficient Ad type 5 vector expressing full-length spike protein)<br/><b>Sponsors</b>:   International Vaccine Institute;   The Coalition for Epidemic Preparedness Innovations (CEPI);   Instituto Nacional de Saúde (INS), Mozambique;   University of Antananarivo;   International Centre for Diarrhoeal Disease Research, Bangladesh;   Harvard University;   Heidelberg University<br/><b>Not yet recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19</strong> - <b>Condition</b>:   COVID-19 Infection<br/><b>Intervention</b>:   Drug: Colchcine<br/><b>Sponsor</b>:  <br/>
 Asociacion Instituto Biodonostia<br/><b>Active, not recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Danicopan;   Other: Placebo;   Drug: Remdesivir<br/><b>Sponsor</b>:   National Institute of Allergy and Infectious Diseases (NIAID)<br/><b>Recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Methylene Blue Antiviral Treatment</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Methylene Blue;   Drug: Saline nasal spray<br/><b>Sponsors</b>:   Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences;   Irkutsk State Medical University<br/><b>Recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Project FLUx COntact-CoVID-19 Faculty of Medicine Paris-Saclay</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Other: Antigenic tests (on saliva samples);   Other: Individual electronic sensor port;   Other: Atmospheric measurements of CO2<br/><b>Sponsor</b>:  <br/>
 Assistance Publique - Hôpitaux de Paris<br/><b>Not yet recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)</strong> - <b>Condition</b>:   COVID-19 Lower Respiratory Infection<br/><b>Interventions</b>:   Biological: AG0302-COVID19 for Intramuscular Injection;   Biological: AG0302-COVID19 for Intradermal Injection<br/><b>Sponsors</b>:   AnGes, Inc.;   Japan Agency for Medical Research and Development<br/><b>Not yet recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Administration of Single-Dose Subcutaneous or Intramuscular Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: casirivimab and imdevimab<br/><b>Sponsor</b>:  <br/>
 Regeneron Pharmaceuticals<br/><b>Not yet recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: Placebo;   Biological: Inactivated vaccine booster;   Biological: mRNA vaccine booster;   Drug: Viral vector vaccine booster<br/><b>Sponsors</b>:   Universidad del Desarrollo;   Ministry of Health, Chile;   University of Chile;   Pontificia Universidad Catolica de Chile<br/><b>Active, not recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Relaxation Exercise in Patients With COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Other: Relaxation technique<br/><b>Sponsor</b>:   Beni- Suef University<br/><b>Completed</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector, Ad5-nCoV) in Adults Living With HIV</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)<br/><b>Sponsors</b>:   Fundación Huésped;   Canadian Center for Vaccinology;   CanSino Biologics Inc.;   Hospital Fernandez<br/><b>Recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Drug: Drug, inhalation<br/><b>Sponsor</b>:  <br/>
 Aquilon Pharmaceuticals S.A.<br/><b>Not yet recruiting</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Dietary Supplement: Artemisinin;   Drug: Dexamethasone<br/><b>Sponsors</b>:   Mateon Therapeutics;   Windlas Biotech Private Limited<br/><b>Completed</b></p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: Inactivated COVID-19 Vaccine;   Biological: Controlled vaccine<br/><b>Sponsor</b>:   Sinovac Research and Development Co., Ltd.<br/><b>Recruiting</b></p></li>
 </ul>
 <h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
 <ul>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Summary report of seven cases of COVID-19 infection in renal transplant recipients</strong> - The coronavirus disease 2019 (COVID-19) has swept the world, posing a serious threat to people’s lives and health. Several cases of COVID-19 infection in renal transplant recipients (RTRs) have been reported, but the treatment and prognosis have not been fully elucidated. We followed-up with RTRs infected with SARS-CoV2 in our center and classified them as five clinical types-asymptomatic, mild, moderate, severe, and critical. The immunosuppressive agents were not adjusted in asymptomatic…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIbeta) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses</strong> - Over half a century since the description of the first antiviral drug, “old” re-emerging viruses and “new” emerging viruses still represent a serious threat for global health. Their high mutation rate and rapid selection of resistance towards common antiviral drugs, together with the increasing number of co-infections, make the war against viruses quite challenging. Here we report a host-targeted approach, based on the inhibition of the lipid kinase PI4KIIIβ, as a promising strategy for…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The rapid diagnosis and effective inhibition of coronavirus using spike antibody attached gold nanoparticles</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the coronavirus disease that began in 2019 (COVID-19), has been responsible for 1.4 million deaths worldwide as of 13 November 2020. Because at the time of writing no vaccine is yet available, a rapid diagnostic assay is very urgently needed. Herein, we present the development of anti-spike antibody attached gold nanoparticles for the rapid diagnosis of specific COVID-19 viral antigen or virus via a simple colorimetric…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A computational study of cooperative binding to multiple SARS-CoV-2 proteins</strong> - Structure-based drug design targeting the SARS-CoV-2 virus has been greatly facilitated by available virus-related protein structures. However, there is an urgent need for effective, safe small-molecule drugs to control the spread of the virus and variants. While many efforts are devoted to searching for compounds that selectively target individual proteins, we investigated the potential interactions between eight proteins related to SARS-CoV-2 and more than 600 compounds from a traditional…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase</strong> - There is currently a lack of effective drugs to treat people infected with SARS-CoV-2, the cause of the global COVID-19 pandemic. The SARS-CoV-2 Non-structural protein 13 (NSP13) has been identified as a target for anti-virals due to its high sequence conservation and essential role in viral replication. Structural analysis reveals two “druggable” pockets on NSP13 that are among the most conserved sites in the entire SARS-CoV-2 proteome. Here we present crystal structures of SARS-CoV-2 NSP13…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients</strong> - Elderly people and patients with comorbidities are at higher risk of COVID-19 infection, resulting in severe complications and high mortality. However, the underlying mechanisms are unclear. In this study, we investigate whether miRNAs in serum exosomes can exert antiviral functions and affect the response to COVID-19 in the elderly and people with diabetes. First, we identified four miRNAs (miR-7-5p, miR-24-3p, miR-145-5p and miR-223-3p) through high-throughput sequencing and quantitative…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Designing Self-Inhibitory fusion peptide analogous to viral spike protein against novel severe acute respiratory syndrome (SARS-CoV-2)</strong> - COVID-19 is a highly contagious viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is declared pandemic by the World Health Organization (WHO). The spike protein of SARS-CoV-2 is a key component playing a pivotal role in facilitating viral fusion as well as release of genome into the host cell. Till date there is no clinically approved vaccine or drug available against Covid-19. We designed four hydrophobic inhibitory peptides (ITPs) based on WWIHS…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19</strong> - At present, global vaccination for the SARS-CoV2 virus 2019 (COVID-19) is 95% effective. Generally, viral infections are arduous to cure due to the mutating nature of viral genomes, with the consequent quick development of resistance, posing significant fatalities or hazards. The novel corona viral strains are increasingly lethal than earlier variants, as those evolve faster than imagined. Despite the emergence of several present innovative treatment options, the vaccines, and available drugs,…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 - associated inhibition of energy accumulation pathways in human semen samples</strong> - CONCLUSION: Our results may provide molecular basis for the previously observed phenomenon of decreased sperm motility associated with COVID-19 infection. Moreover, identified data would be beneficial for the optimization of preconception care for men who have recently recovered from COVID-19.</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The role of T2E mediated CBF-1/RBP-Jκ signaling in metastatic thyroid cancer</strong> - CONCLUSION: This study indicates that the overexpression of ERG co-option has a unique cis-regulatory structure in T2E positive thyroid tumors, which induces drug dependence on CBF-1/RBP-Jκ signal. Our study solved the genetic and epigenetic variation of T2E in metastatic thyroid cancer for the first time. It is worth noting that further functional and clinical validation is needed as our study is a bioinformatics analysis.</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Transmissible gastroenteritis virus ORF3b up-regulates miR-885-3p to counteract TNF-alpha production via inhibiting NF-kappaB pathway</strong> - Transmissible gastroenteritis (TGE) is an acute viral disease and characterized as severe acute inflammation response that leads to diarrhea, vomiting, and high lethality of piglets. Transmissible gastroenteritis virus (TGEV), a member of coronavirus, is the pathogen of TGE. We previously found NF-κB pathway was activated and 65 miRNAs were changed in response to inflammation caused by TGEV in cell line porcine intestinal epithelial cells-jejunum 2 (IPEC-J2). Bioinformatics results showed that…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The use of pseudotyped coronaviruses for the screening of entry inhibitors: Green tea extract inhibits the entry of SARS-CoV-1, MERS-CoV, and SARS-CoV-2 by blocking receptor-spike interaction</strong> - CONCLUSION: In summary, we demonstrated that pseudotyped viruses are an ideal tool for studying viral entry, quantification of neutralizing antibodies, and screening of entry inhibitors in a BSL-2 facility. Moreover, green tea might be a promising natural remedy against emerging coronaviruses.</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In Vitro Inhibition of Alphaviruses by Lycorine</strong> - Chikungunya virus (CHIKV) is a mosquito-borne alphavirus. As an emerging virus, CHIKV imposes a threat to public health. Currently, there are no vaccines or antivirals available for the prevention of CHIKV infection. Lycorine, an alkaloid from Amaryllidaceae plants, has antiviral activity against a number of viruses such as coronavirus, flavivirus and enterovirus. In this study, we found that lycorine could inhibit CHIKV in cell culture at a concentration of 10 μmol/L without apparent…</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review</strong> - CONCLUSIONS AND RELEVANCE: Adverse events like VITT, while uncommon, have been described despite vaccination remaining the most essential component in the fight against the COVID-19 pandemic. While it seems logical to consider the use of types of vaccines (eg, mRNA-based administration) in individuals at high risk, treatment should consist of therapeutic anticoagulation mostly with nonheparin products and IVIG.</p></li>
 <li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dietary foods containing nitric oxide donors can be early curators of SARS-CoV-2 infection: A possible role in the immune system</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is a lethal virus that causes COVID-19 (Coronavirus disease 2019), the respiratory illness that has caused the COVID-19 pandemic. Even though multiple pharmacological trials are ongoing, there is no proof that any treatment will effectively cure or prevent COVID-19. Currently, COVID-19-infected patients are being managed with non-specific medications to suppress the symptoms and other associated co-morbidities. Nitric oxide is a…</p></li>
 </ul>
 <h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
 <ul>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>자외선살균등</strong> - 본 발명은 사람의 의복이나 사용한 마스크 등에 부착하여 있다 호흡기로 유입되어 감염을 유발할 수 있는 COVID-19와 같은 유해균류를 간편하게 살균하기 위한 휴대용 자와선살균등에 관한 것이다. 반감기가 길고 인체에 유해한 오존을 발생하지 않으면서 탁월한 살균능력이 있는 250~265nm(최적은 253.7nm) 파장의 자외선을 발광하는 자외선램프를 본 발명의 막대형의 자외선살균등 광원으로 사용하고 비광원부를 손으로 잡고 의복이나 사용한 마스크 등 유해균류가 부착되었을 것으로 의심되는 곳에 자외선을 조사하여 간편하게 유해균류를 살균하므로써 감염을 예방하기 위한 휴대용 자외선살균등에 관함 것이다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR332958765">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Camellia nitidissima C.W.Chi Caffeine and Chlorogenic acid composition for anti-SARS-CoV-2 and preparation method and application thereof</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU331907401">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Novel Method COVID -19 infection using Deep Learning Based System</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU331907400">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A SYSTEM AND METHOD FOR COVID- 19 DIAGNOSIS USING DETECTION RESULTS FROM CHEST X- RAY IMAGES</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU330927328">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mascarilla impermeable</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=ES329916792">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法</strong> - 本申请公开了一种基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法。具体而言，本公开中提供了一种在其细胞膜表面展示新型冠状病毒SARS‑CoV‑2刺突蛋白S的细胞，包含所述细胞的针对新型冠状病毒SARS‑CoV‑2的疫苗或疫苗组合，所述细胞在制备用于预防或治疗新型冠状病毒SARS‑CoV‑2的疫苗中的应用及其制备方法。本公开的细胞和疫苗能够在体内高效活化B细胞，诱导中和抗体应答，在预防和降低新冠病毒感染中有广泛的应用前景。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN332882580">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>硫代咪唑烷酮药物在治疗COVID-19疾病中的用途</strong> - 本发明属于医药技术领域，具体涉及一种硫代咪唑烷酮药物或其药学上可接受的盐在制备用于治疗ACE2和TMPRSS2蛋白失调相关疾病的药物中的用途，尤其是在制备用于治疗COVID‑19疾病的药物中的用途。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN332882591">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Advanced Machine Learning System combating COVID-19 virus Detection, Spread, Prevention and Medical Assistance.</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU329799475">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种包装重组流感病毒的重组载体和重组流感病毒及其构建方法和应用</strong> - 本发明提供了一种包装重组流感病毒的重组载体和重组流感病毒及其构建方法和应用，涉及生物医药技术领域。本发明利用A型流感病毒八个基因片段为骨架包装出带有新型冠状病毒SARS‑CoV‑2表面刺突蛋白受体结合域（SARS‑CoV‑2_RBD）片段的重组流感病毒，此重组流感病毒可在复制过程中表达具有生物学活性和免疫原性的刺突蛋白受体结合区域RBD。本发明所述重组流感病毒rgH1N1（PR8）‑PA‑RBD可作为重组病毒类药物，用于2019新型冠状病毒肺炎（COVID‑19）的预防；也可作为体外SARS‑COV‑2 RBD等相关抗原表达和体内递呈系统。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN331407402">link</a></p></li>
 <li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Differential detection kit for common SARS-CoV-2 variants in COVID-19 patients</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU328840861">link</a></p></li>
 </ul>
 <script>AOS.init();</script></body></html>
--- a/archive-daily-dose/13
+++ b/archive-daily-dose/13
--- a/index.html
+++ b/index.html